PL2249864T3 - Strategie zapobiegania i/lub leczenia odpowiedzi immunologicznych na rozpuszczalne alloczynniki - Google Patents
Strategie zapobiegania i/lub leczenia odpowiedzi immunologicznych na rozpuszczalne alloczynnikiInfo
- Publication number
- PL2249864T3 PL2249864T3 PL09710097.8T PL09710097T PL2249864T3 PL 2249864 T3 PL2249864 T3 PL 2249864T3 PL 09710097 T PL09710097 T PL 09710097T PL 2249864 T3 PL2249864 T3 PL 2249864T3
- Authority
- PL
- Poland
- Prior art keywords
- strategies
- prevent
- immune responses
- treat immune
- soluble allofactors
- Prior art date
Links
- 230000028993 immune response Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08447010 | 2008-02-14 | ||
US3580008P | 2008-03-12 | 2008-03-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2249864T3 true PL2249864T3 (pl) | 2016-11-30 |
Family
ID=40874994
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL09710097.8T PL2249864T3 (pl) | 2008-02-14 | 2009-02-16 | Strategie zapobiegania i/lub leczenia odpowiedzi immunologicznych na rozpuszczalne alloczynniki |
Country Status (7)
Country | Link |
---|---|
US (3) | US20100330088A1 (pl) |
EP (2) | EP3075391A1 (pl) |
AU (1) | AU2009214040B2 (pl) |
CA (1) | CA2724440C (pl) |
ES (1) | ES2584430T3 (pl) |
PL (1) | PL2249864T3 (pl) |
WO (1) | WO2009101206A2 (pl) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2476437B1 (en) | 2006-08-11 | 2018-11-28 | Life Sciences Research Partners VZW | Immunogenic peptides and their use in immune disorders |
CA2715517C (en) * | 2008-02-14 | 2018-07-24 | Life Sciences Research Partners Vzw | Immunogenic peptides and their use in preventing or treating allograft rejection |
EP2245059B1 (en) | 2008-02-14 | 2017-09-20 | Life Sciences Research Partners VZW | Cd4+ t-cells with cytolytic properties |
EP2623124A1 (en) | 2008-02-14 | 2013-08-07 | Life Sciences Research Partners VZW | Elimination of immune responses to viral vectors |
WO2009101205A2 (en) | 2008-02-14 | 2009-08-20 | Life Sciences Research Partners Vzw | Immunogenic control of tumours and tumour cells |
US20120009678A1 (en) | 2008-02-14 | 2012-01-12 | Jean-Marie Saint-Remy | Immunotherapy targeting intracellular pathogens |
EP2742949A1 (en) * | 2009-11-13 | 2014-06-18 | Puget Sound Blood Center | Factor VIII B cell epitope variants having reduced immunogenicity |
DK2643345T5 (da) * | 2010-11-25 | 2021-05-17 | Imnate Sarl | Immunogene peptider til anvendelse til forebyggelse og/eller behandling af infektionssygdomme, autoimmune sygdomme, immunresponser på allofaktorer, allergisygdomme, tumorer, transplantatafstødning og immunresponser på virusvektorer anvendt til genterapi eller genvaccination |
GB201201511D0 (en) * | 2012-01-30 | 2012-03-14 | Univ Leuven Kath | Modified epitopes for boosting CD4+ T-cell responses |
EP2666782A1 (en) | 2012-05-22 | 2013-11-27 | Imnate Sarl | Coagulation factor VIII with reduced immunogenicity. |
GB201309469D0 (en) | 2013-05-28 | 2013-07-10 | Imcyse Sa | Detection of CD4+ T lymphocytes |
GB201418433D0 (en) | 2014-10-17 | 2014-12-03 | Imcyse Sa | Novel immunogenic peptides |
US10729791B2 (en) | 2015-05-18 | 2020-08-04 | Imcyse Sa | Animal models for evaluating pharmaceutical compounds |
ES2874077T3 (es) * | 2015-09-25 | 2021-11-04 | Imcyse Sa | Métodos y compuestos mejorados para eliminar respuestas inmunitarias a agentes terapéuticos |
KR20180134935A (ko) | 2016-04-19 | 2018-12-19 | 임시스 에스에이 | 신규 면역원성 CD1d 결합 펩티드 |
PE20191529A1 (es) | 2017-03-09 | 2019-10-23 | Imcyse Sa | Peptidos y metodos para el tratamiento de diabetes |
US20210401976A1 (en) | 2018-11-12 | 2021-12-30 | Imcyse Sa | Immunogenic peptides with improved oxidoreductase motifs |
CN115867567A (zh) | 2020-05-06 | 2023-03-28 | 易姆赛斯股份公司 | 具有新氧化还原酶基序的免疫原性肽 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4886782A (en) * | 1987-02-26 | 1989-12-12 | The United States Of America As Represented By The Department Of Health And Human Services | Malarial immunogen |
US5589582A (en) * | 1992-10-27 | 1996-12-31 | Biotransplant, Inc. | Polynucleotides en coding porcine cytokines |
US8791237B2 (en) * | 1994-11-08 | 2014-07-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of non-hodgkins lymphoma |
US7157089B1 (en) * | 1996-11-26 | 2007-01-02 | Stressgen Biotechnologies Corporation | Immune responses using compositions containing stress proteins |
NO315238B1 (no) * | 1998-05-08 | 2003-08-04 | Gemvax As | Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy |
GB0006437D0 (en) * | 2000-03-17 | 2000-05-10 | Leuven Res & Dev Vzw | Compounds for the modulation of allergen sensitivity by antigens sharing T cell epitopes with allergens |
AU2001272491A1 (en) * | 2000-06-26 | 2002-01-08 | Smithkline Beecham Biologicals (S.A.) | Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest |
US7049413B2 (en) * | 2001-05-18 | 2006-05-23 | Ludwig Institute For Cancer Research | MAGE-A3 peptides presented by HLA class II molecules |
US6854590B2 (en) * | 2001-07-24 | 2005-02-15 | Fmc Technologies, Inc. | Conveyor belt assembly |
US7651855B2 (en) * | 2003-04-17 | 2010-01-26 | The Trustees Of The University Of Pennsylvania | Regulatory T cells and their use in immunotherapy and suppression of autoimmune responses |
FR2898275B1 (fr) * | 2006-03-10 | 2012-12-14 | Genethon | Cellules t regulatrices cd4+cd25+specifiques pour la greffe de cellules hematopoietiques et la tolerance immunitaire |
EP2476437B1 (en) * | 2006-08-11 | 2018-11-28 | Life Sciences Research Partners VZW | Immunogenic peptides and their use in immune disorders |
US20120009678A1 (en) * | 2008-02-14 | 2012-01-12 | Jean-Marie Saint-Remy | Immunotherapy targeting intracellular pathogens |
CA2715517C (en) * | 2008-02-14 | 2018-07-24 | Life Sciences Research Partners Vzw | Immunogenic peptides and their use in preventing or treating allograft rejection |
WO2009101205A2 (en) * | 2008-02-14 | 2009-08-20 | Life Sciences Research Partners Vzw | Immunogenic control of tumours and tumour cells |
EP2623124A1 (en) * | 2008-02-14 | 2013-08-07 | Life Sciences Research Partners VZW | Elimination of immune responses to viral vectors |
CN103002909B (zh) * | 2010-03-29 | 2016-06-29 | 国家科学研究中心 | 包含含有至少一个cxxc基序的多肽和异源抗原的药物组合物及其用途 |
PE20191529A1 (es) * | 2017-03-09 | 2019-10-23 | Imcyse Sa | Peptidos y metodos para el tratamiento de diabetes |
-
2009
- 2009-02-16 PL PL09710097.8T patent/PL2249864T3/pl unknown
- 2009-02-16 US US12/735,739 patent/US20100330088A1/en not_active Abandoned
- 2009-02-16 CA CA2724440A patent/CA2724440C/en active Active
- 2009-02-16 AU AU2009214040A patent/AU2009214040B2/en active Active
- 2009-02-16 EP EP16161449.0A patent/EP3075391A1/en not_active Withdrawn
- 2009-02-16 WO PCT/EP2009/051806 patent/WO2009101206A2/en active Application Filing
- 2009-02-16 EP EP09710097.8A patent/EP2249864B1/en active Active
- 2009-02-16 ES ES09710097.8T patent/ES2584430T3/es active Active
-
2016
- 2016-12-22 US US15/388,398 patent/US20170100466A1/en not_active Abandoned
-
2019
- 2019-12-24 US US16/726,411 patent/US20200179499A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2009214040A1 (en) | 2009-08-20 |
EP3075391A1 (en) | 2016-10-05 |
EP2249864A2 (en) | 2010-11-17 |
US20200179499A1 (en) | 2020-06-11 |
US20170100466A1 (en) | 2017-04-13 |
CA2724440A1 (en) | 2009-08-20 |
WO2009101206A3 (en) | 2011-02-17 |
AU2009214040B2 (en) | 2013-08-22 |
EP2249864B1 (en) | 2016-05-04 |
CA2724440C (en) | 2018-01-09 |
ES2584430T3 (es) | 2016-09-27 |
WO2009101206A2 (en) | 2009-08-20 |
US20100330088A1 (en) | 2010-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2249864T3 (pl) | Strategie zapobiegania i/lub leczenia odpowiedzi immunologicznych na rozpuszczalne alloczynniki | |
ZA201302979B (en) | Dianosis and treatment relating to th2 inhibition | |
IL208518A0 (en) | Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions | |
HRP20140203T1 (hr) | Pripravci i metode za jaäśanje imunološkog sustava | |
EP2111231A4 (en) | METHODS AND COMPOSITIONS FOR IMPROVING IMMUNE RESPONSES | |
IL214403A0 (en) | Novelcell lines and methods | |
EP2360155A4 (en) | 2-AMINOPYRIDIN-4-ON AND 2-AMINOPYRIDINE DERIVATIVE WITH BACE1-HEMDERING EFFECT | |
EP2449102A4 (en) | ARGINASE FORMULATIONS AND METHODS | |
HK1221478A1 (zh) | 變體及其用途 | |
GB0819720D0 (en) | Methods and products | |
IL215932A0 (en) | Compositions and methods for treating burns | |
HK1161720A1 (en) | Dihydroetorphines and their preparation | |
HK1186680A1 (zh) | 包含泡桐素和/或泡桐屬提取物的組合物及其用途 | |
EP2497154A4 (en) | CONNECTOR AND ASSOCIATED METHODS OF USE | |
EP2385935A4 (en) | COMPOUNDS AND APPLICATIONS THEREFOR FOR TREATING INFLAMMATION AND FOR MODULATING IMMUNE REACTIONS | |
EP2155239A4 (en) | METHOD FOR REDUCING IMMUNE RESPONSE AND TREATMENT OF IMMUNE DISEASES | |
IL214757A0 (en) | Compositions and methods to prevent and/or treat cancer with pa-card | |
IL209220A0 (en) | Plant extract and its therapeutic use | |
GB0912744D0 (en) | Methods and uses | |
EP2498807A4 (en) | COMPOSITION, METHODS, AND APPLICATIONS OF STIMULATION OF IMMUNE RESPONSES | |
AU2013263774A1 (en) | Strategies to prevent and/or treat immune responses to soluble allofactors | |
GB0813359D0 (en) | Halfin and/or platerfin | |
GB0803731D0 (en) | Methods and products | |
GB0820562D0 (en) | Novel use and treatment | |
GB0816523D0 (en) | Methods and uses |